BriaCell Therapeutics Corp. (BCTX) Form 10-Q — Jun 9, 2026
BriaCell Therapeutics reported a net loss of $22.6 million for the nine months ended April 30, 2026, driven by $18.7 million in R&D expenses as it advances its pivotal Phase 3 breast cancer trial. The company holds $22.8 million in total liquidity (cash and short-term investments) but disclosed substantial doubt about its ability to continue as a going concern, noting dependence on future financing. Despite the financial headwinds, BriaCell highlighted significant clinical momentum, including a feature in Nature Medicine’s Year in Review and positive Phase 2 survival data showing patients living 18-47 months post-enrollment.
Key figures
- Total Debt
- 71854
- Total Assets
- 27071310
- Cash Position
- 6880221
- Shares Outstanding
- 7250487
- Total Liquidity
- 22804425
- Jan2026 Offering Price
- 5.59
- Rd Expenses Nine Months
- 18704005
- Short Term Investments
- 15924204
- Jan2026 Offering Shares
- 5366726
- June2026 Offering Price
- 3.25
- June2026 Offering Shares
- 1449300
- Briapro Ownership Percent
- 78
- Jan2026 Offering Proceeds
- 30000000
- June2026 Offering Proceeds
- 4700000
- Bc Therapeutics Ownership Percent
- 69.04
Price after filing
Close on the filing date to close N calendar days later (from $3.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.